Table 1.
Baseline comparisons in the Triple-negative group (grouped according to the group-based trajectory of CA72-4)
| characteristic | Total | Normal N = 80 |
Elevated N = 25 |
Descend N = 22 |
Stable N = 29 |
p-value1 |
|---|---|---|---|---|---|---|
| Age, n(%) | 0.127 | |||||
| ≤ 60 | 63(40.4) | 31(38.8) | 14(56) | 5(22.7) | 13(44.8) | |
| > 60 | 93(59.6) | 49(61.3) | 11(44) | 17(77.3) | 16(55.2) | |
| Sex, n(%) | 0.034 | |||||
| Male | 112(71.8) | 56(70) | 18(72) | 21(95.5) | 17(58.6) | |
| Female | 44(28.2) | 24(30) | 7(28) | 1(4.5) | 12(41.4) | |
| ECOG scores, n(%) | 0.995 | |||||
| 0 | 97(62.2) | 50(62.5) | 15(60) | 14(63.6) | 18(62.1) | |
| 1/2 | 59(37.8) | 30(37.5) | 10(40) | 8(36.4) | 11(37.9) | |
| ypT, n(%) | 0.058 | |||||
| 0/1 | 24(15.4) | 12(15) | 9(36) | 3(13.6) | 0 | |
| 2 | 33(21.2) | 16(20) | 2(8) | 6(27.3) | 9(31) | |
| 3 | 60(38.4) | 33(41.3) | 7(28) | 8(36.4) | 12(41.4) | |
| 4 | 39(25) | 19(23.7) | 7(28) | 5(22.7) | 8(27.6) | |
| ypN, n(%) | 0.774 | |||||
| 0 | 62(39.8) | 31(38.8) | 11(44) | 10(45.5) | 10(34.5) | |
| 1 | 36(23.1) | 20(25) | 6(24) | 6(27.3) | 4(13.8) | |
| 2 | 30(19.2) | 17(21.2) | 3(12) | 3(13.6) | 7(24.1) | |
| 3 | 28(17.9) | 12(15) | 5(20) | 3(13.6) | 8(27.6) | |
| Location, n(%) | 0.560 | |||||
| Upper | 65(41.7) | 35(43.8) | 9(36) | 7(31.8) | 14(48.3) | |
| Middle | 37(23.7) | 16(20) | 6(24) | 8(36.4) | 7(24.1) | |
| Lower | 43(27.6) | 26(32.5) | 7(28) | 5(22.7) | 5(17.3) | |
| Mixed | 11(7) | 3(3.7) | 3(12) | 2(9.1) | 3(10.3) | |
| Lymphovascular Invasion, n(%) | 0.388 | |||||
| No | 96(61.5) | 53(66.3) | 16(64) | 13(59.1) | 14(48.3) | |
| Yes | 60(38.5) | 27(33.7) | 9(36) | 9(40.9) | 15(51.7) | |
| Neural Invasion, n(%) | 0.400 | |||||
| No | 68(43.6) | 33(41.3) | 13(52) | 12(54.5) | 10(34.5) | |
| Yes | 88(56.4) | 47(58.7) | 12(48) | 10(45.5) | 19(65.5) | |
| TRG grade, n(%) | 0.625 | |||||
| 0/1 | 39(25) | 18(22.5) | 8(32) | 7(31.8) | 6(20.7) | |
| 2/3 | 117(75) | 62(77.5) | 17(68) | 15(68.2) | 23(79.3) | |
| NACT regimens, n(%) | 0.995 | |||||
| Platinum based | 64(41) | 32(40) | 11(44) | 8(36.4) | 13(44.8) | |
| Paclitaxel based | 63(40.4) | 33(41.3) | 10(40) | 9(40.9) | 11(37.9) | |
| Others | 29(18.6) | 15(18.7) | 4(16) | 5(22.7) | 5(17.3) | |
| NACT cycles, Median (IQR) | 4(3–4) | 4(3–4) | 3(3–4) | 4(3–4) | 3(3–4) | 0.735 |
| AC regimes, n(%) | 0.986 | |||||
| Platinum based | 55(41.4) | 27(40.9) | 11(45.8) | 7(33.3) | 10(45.4) | |
| Paclitaxel based | 52(39.1) | 26(39.4) | 9(37.5) | 9(42.9) | 8(36.4) | |
| Others | 26(19.5) | 13(19.7) | 4(16.7) | 5(23.8) | 4(18.2) | |
| AC, n(%) | 0.178 | |||||
| No | 19(12.2) | 11(13.8) | 1(4) | 1(4.5) | 6(20.7) | |
| Yes | 137(87.8) | 69(86.3) | 24(96) | 21(95.5) | 23(79.3) | |
| Complication, n(%) | 0.349 | |||||
| No | 140(89.7) | 75(93.8) | 22(88) | 19(86.4) | 24(82.8) | |
| Yes | 16(10.3) | 5(6.3) | 3(12) | 3(13.6) | 5(17.2) | |
| LOS, Median (IQR) | 8(7–10) | 8(7–10) | 8(7–9) | 8(7–9) | 9(7–12) | 0.282 |
| Operative time, Median (IQR) |
185 (157–220) |
190 (160–225) |
180 (150–210) |
199 (165–210) |
180 (155–221) |
0.277 |
| Bleed, Median (IQR) | 35(30–50) | 35(30–50) | 30(30–50) | 40(30–50) | 30(30–60) | 0.861 |
1: One-way ANOVA; Pearson’s Chi-squared test; Fisher’s exact test
Bold values indicated that the P value < 0.05
Abbreviation ECOG score: Eastern Cooperative Oncology Group (ECOG) Performance Status score; ypT: Tumor (T pathological stage) after neoadjuvant chemotherapy; ypN: Nodes pathological stage after neoadjuvant chemotherapy; TRG: Tumor Regression Grade; NACT: Neoadjuvant chemotherapy; CA72-4: Carbohydrate antigen 72 − 4; LOS: length of stay